Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Rare diseases and orphan drugs: Our experience and expertise
We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs, which includes links to...
Conducting research for publication video
APAC Director Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their real value to patients, healthcare and society.Watch the video: https://bit.ly/2OcOWNu
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Portfolio analysis: Using market research to master communications across a therapeutic category
Many of us are familiar with billiard games, where two players compete to be the first to pocket all the balls on the table in a particular order. We recently...
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Patients’willingness to pay
Considerations when developing an appropriate pricing strategy in self-pay markets
Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report
Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...
Scratching the surface: unmet needs in psoriasis
Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...
Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination
Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...
Conference Live for ongoing congress performance measurement
Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year